Drug
auy922 clinical trials
Also written AUY922.
- studies test it
- 23
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
- AUY922
- 21
Studies by the year they started
23 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 4 |
| 2011 | 7 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 16
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 14
Novartis Pharmaceuticals (9) · SCRI Development Innovations, LLC (2) · Massachusetts General Hospital (2) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · National Taiwan University Hospital (1) · Swedish Medical Center (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Trastuzumab (2) · Capecitabine (1) · Ceritinib (1) · Alpelisib (1) · Pemetrexed (1) · Erlotinib (1) · Cetuximab (1)
Studies
Open first, then newest update. How each study uses auy922 is read from its arms, and is right about nine times in ten.
Testing it · 23
- A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid TumorsCompletedPhase 1SCRI Development Innovations, LLCNCT01226732Written as Hsp90 Inhibitor AUY 922
- Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerCompletedPhase 1Novartis PharmaceuticalsNCT01772797Written as AUY922
- Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer PatientsCompletedPhase 1/2Novartis PharmaceuticalsNCT00526045Written as AUY922 2 mg/m2
- Phase II Trial of AUY922 vs. Comparators in Advanced Gastric CancerCompletedPhase 2Novartis PharmaceuticalsNCT01084330Written as AUY922
- Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive PatientsTerminatedPhase 2Novartis PharmaceuticalsNCT01402401Written as AUY922
- Dose Escalation Study of AUY922 in Advanced Solid Malignancies in JapanCompletedPhase 1Novartis PharmaceuticalsNCT01132625Written as AUY922
- PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric CancerCompletedPhase 1Novartis PharmaceuticalsNCT01613950Written as AUY922
- Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabCompletedPhase 1/2Novartis PharmaceuticalsNCT01271920Written as AUY922
- Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT01784640Written as Hsp90 inhibitor AUY922
- Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerCompletedPhase 1/2Northwestern UniversityNCT01259089Written as Hsp90 inhibitor AUY922
- An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsTerminatedPhase 2Novartis PharmaceuticalsNCT01646125Written as AUY922
- Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line ChemotherapyTerminatedPhase 2University Health Network, TorontoNCT01484860Written as AUY922
- AUY922 in Patient With Stage IV NSCLCCompletedPhase 2National Taiwan University HospitalNCT01922583Written as AUY922
- Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFRCompletedPhase 2Massachusetts General HospitalNCT01854034Written as AUY922
- AUY922 for Advanced ALK-positive NSCLCCompletedPhase 2Massachusetts General HospitalNCT01752400Written as AUY922
- AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast CancerWithdrawnPhase 1/2Texas Tech University Health Sciences Center, El PasoNCT01361945Written as AUY922
- A Study of the HSP90 Inhibitor AUY922TerminatedPhase 2M.D. Anderson Cancer CenterNCT01485536Written as AUY922
- Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal TumorCompletedPhase 2SCRI Development Innovations, LLCNCT01404650Written as AUY922
- HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT01668173Written as AUY922
- A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.CompletedPhase 2Novartis PharmaceuticalsNCT01124864Written as AUY922
See all 23 studies that test auy922 →
Given in every arm · 1 — auy922 is usual care beside what is tested
Codes
What other systems call auy922 · ClinicalTrials.gg INT005255
- UNII (FDA) G1G66XE93WAUY922Confirmed FDA, Wikidata
- Wikidata Q27278569auy922Confirmed FDA, Wikidata
- DrugBank DB11881One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G1G66XE93W | AUY922 | Confirmed FDA, Wikidata |
| Wikidata | Q27278569 | auy922 | Confirmed FDA, Wikidata |
| DrugBank | DB11881 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.